Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.36 -2.3%	$3.27	$2.71 ▼ $4.73	$643.53M	1.5	991,875 shs	635,966 shs
ARCT Arcturus Therapeutics	$12.63 -0.8%	$11.30	$8.04 ▼ $45.00	$339.83M	2.36	448,762 shs	1.00 million shs
BTAI BioXcel Therapeutics	$1.18 -4.1%	$1.67	$1.17 ▼ $29.28	$7.15M	0.08	1.20 million shs	162,010 shs
JANX Janux Therapeutics	$23.71 -1.4%	$27.37	$22.48 ▼ $71.71	$1.41B	3.24	884,498 shs	1.06 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	+4.35%	-6.93%	-2.61%	0.00%
ARCT Arcturus Therapeutics	0.00%	+3.52%	+1.04%	-24.78%	-65.60%
BTAI BioXcel Therapeutics	0.00%	-15.11%	-33.33%	-45.37%	-95.88%
JANX Janux Therapeutics	0.00%	-5.99%	-26.02%	-27.91%	-50.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	1.9877 of 5 stars	3.5	0.0	0.0	2.7	2.5	0.6
ARCT Arcturus Therapeutics	2.8365 of 5 stars	4.6	0.0	0.0	2.5	2.5	0.6
BTAI BioXcel Therapeutics	3.9994 of 5 stars	3.3	3.0	4.5	2.0	1.7	0.6
JANX Janux Therapeutics	2.271 of 5 stars	3.5	0.0	0.0	4.0	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	63.69% Upside
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	323.59% Upside
BTAI BioXcel Therapeutics	2.67	Moderate Buy	$42.60	3,510.17% Upside
JANX Janux Therapeutics	3.09	Buy	$95.25	301.73% Upside

Current Analyst Ratings Breakdown

Latest BTAI, JANX, ARCT, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
4/10/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/19/2025	BTAI BioXcel Therapeutics	RODMAN&RENSHAW Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/19/2025	BTAI BioXcel Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00
3/10/2025	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
3/10/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $68.00
3/7/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$63.00 ➝ $60.00

(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.40M	100.50	N/A	N/A	$0.63 per share	5.33
ARCT Arcturus Therapeutics	$131.27M	2.61	N/A	N/A	$10.42 per share	1.21
BTAI BioXcel Therapeutics	$1.85M	3.86	N/A	N/A	($30.21) per share	-0.04
JANX Janux Therapeutics	$9.34M	150.28	N/A	N/A	$7.46 per share	3.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$72.85M	-$0.41	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	7/31/2025 (Estimated)
ARCT Arcturus Therapeutics	-$29.73M	-$2.53	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	8/4/2025 (Estimated)
BTAI BioXcel Therapeutics	-$179.05M	-$13.55	N/A	N/A	N/A	-3,119.33%	N/A	-105.04%	8/5/2025 (Estimated)
JANX Janux Therapeutics	-$58.29M	-$1.36	N/A	N/A	N/A	-463.91%	-10.47%	-9.86%	8/6/2025 (Estimated)

Latest BTAI, JANX, ARCT, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/12/2025	Q1 2025	BTAI BioXcel Therapeutics	-$2.72	-$1.50	+$1.22	-$1.50	$0.35 million	$0.17 million
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million
3/27/2025	Q4 2024	BTAI BioXcel Therapeutics	-$4.36	-$3.57	+$0.79	-$3.57	$0.72 million	$0.30 million
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$0.71	5.66%	N/A	N/A	N/A
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	7.02	7.02
ARCT Arcturus Therapeutics	N/A	4.76	4.76
BTAI BioXcel Therapeutics	N/A	1.87	1.81
JANX Janux Therapeutics	N/A	38.80	38.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ARCT Arcturus Therapeutics	94.54%
BTAI BioXcel Therapeutics	30.68%
JANX Janux Therapeutics	75.39%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
ARCT Arcturus Therapeutics	16.60%
BTAI BioXcel Therapeutics	21.20%
JANX Janux Therapeutics	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	181.91 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
BTAI BioXcel Therapeutics	90	6.06 million	2.44 million	Optionable
JANX Janux Therapeutics	30	59.18 million	37.05 million	Optionable

BTAI, JANX, ARCT, and ABUS Headlines

Recent News About These Companies

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Wellington Management Group LLP

June 1 at 4:57 AM | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

June 1 at 4:21 AM | marketbeat.com

Two Sigma Investments LP Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

May 31 at 3:47 AM | marketbeat.com

Nuveen Asset Management LLC Sells 39,145 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 31 at 3:37 AM | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Squarepoint Ops LLC

May 30 at 3:54 AM | marketbeat.com

Janux Therapeutics (NASDAQ:JANX) Stock Price Down 4.2% - Should You Sell?

May 29 at 4:16 PM | marketbeat.com

Millennium Management LLC Invests $6.22 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

May 29 at 3:38 AM | marketbeat.com

Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) Target Price at $95.25

May 23, 2025 | americanbankingnews.com

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Has $22.99 Million Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

May 22, 2025 | marketbeat.com

Woodline Partners LP Buys 251,924 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 22, 2025 | marketbeat.com

Rafferty Asset Management LLC Sells 13,522 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 22, 2025 | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by Analysts

May 22, 2025 | marketbeat.com

Deutsche Bank AG Purchases 73,912 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 21, 2025 | marketbeat.com

Troluce Capital Advisors LLC Buys New Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

May 20, 2025 | marketbeat.com

50,000 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Purchased by Tang Capital Management LLC

May 20, 2025 | marketbeat.com

Point72 Asset Management L.P. Boosts Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

May 19, 2025 | marketbeat.com

Sphera Funds Management LTD. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

May 18, 2025 | marketbeat.com

Lazard Asset Management LLC Buys New Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

May 18, 2025 | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) is Prosight Management LP's 10th Largest Position

May 17, 2025 | marketbeat.com

Bank of America Corp DE Purchases 731,962 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 17, 2025 | marketbeat.com

Northern Trust Corp Buys 42,302 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI, JANX, ARCT, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.36 -0.08 (-2.33%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.34 -0.02 (-0.60%)

As of 05/30/2025 05:43 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arcturus Therapeutics NASDAQ:ARCT

$12.63 -0.10 (-0.79%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$12.60 -0.03 (-0.25%)

As of 05/30/2025 05:54 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

BioXcel Therapeutics NASDAQ:BTAI

$1.18 -0.05 (-4.07%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.22 +0.04 (+3.39%)

As of 05/30/2025 07:56 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Janux Therapeutics NASDAQ:JANX

$23.71 -0.33 (-1.37%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$24.48 +0.77 (+3.25%)

As of 05/30/2025 07:58 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time